bluebird bio Rebrands as Genetix Biotherapeutics, Returning to Its Foundational RootsBusiness Wire • 09/18/25
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender OfferBusiness Wire • 05/30/25
bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK CapitalBusiness Wire • 05/27/25
Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender InstructionsBusiness Wire • 05/16/25
bluebird bio shares soar after amended buyout offer from Carlyle, SK CapitalProactive Investors • 05/14/25
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK CapitalBusiness Wire • 05/09/25
Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bioBusiness Wire • 05/05/25
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagementBusiness Wire • 04/16/25
Bluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- UpdateMarket Watch • 03/28/25
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from AyrmidBusiness Wire • 03/28/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bluebird Bio, Inc. - BLUEAccesswire • 03/19/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUEPRNewsWire • 03/17/25
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUEBusiness Wire • 03/13/25
bluebird bio Investor Alert: Is the Proposed Acquisition of bluebird bio Fair to bluebird bio Investors - Kehoe Law Firm, P.C. Investigating - BLUEAccesswire • 03/12/25
Blue Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Bluebird Bio, Inc. is Fair to ShareholdersAccesswire • 03/05/25
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc.PRNewsWire • 02/21/25
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy makerCNBC • 02/21/25